Table 1.
Proposed and completed clinical trials registered in the FDA database
| Rank | Status | Study | Intervention |
|---|---|---|---|
| 1 | Recruiting | Stem cell therapy for patients with multiple sclerosis failing interferon a randomized study | Procedure: hematopoietic stem cell therapy |
| 2 | Active, not recruiting | Hematopoietic stem cell therapy for patients with multiple sclerosis | Procedure: hematopoietic stem cell transplantation |
| 3 | Active, not recruiting | Donor stem cell transplantation for the treatment of multiple sclerosis | Procedure: stem cell transplant |
| 4 | Active, not recruiting | High‐dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study | Drug: granulocyte‐colony stimulating factor (G‐CSF) and prednisone; Drug: carmustine, etoposide, cytarabine, and melphalan (BEAM); Procedure: autologous hematopoietic stem cell transplant |
| 5 | Recruiting | Autologous mesenchymal stem cells from adipose tissue in patients with secondary progressive multiple sclerosis | Other: autologous mesenchymal stem cells from adipose tissue |
| 6 | Active, not recruiting | Mesenchymal stem cells in multiple sclerosis (MSCIMS) | Procedure: MSC treatment |
| 7 | Active, not recruiting | Mesenchymal stem cells for the treatment of MS | Biological: injection of autologous stem cells |
| 8 | Completed | Immunological mechanisms of hematopoietic stem cell transplantation in multiple sclerosis | Procedure: stem cell transplantation |
| 9 | Completed | High dose chemo/radiotherapy and hematopoietic stem cell transplant for patients with multiple sclerosis | Drug: cyclophosphamide; Drug: ATG; drug: MESNA; Procedure: radiation therapy |
| 10 | Not yet recruiting | Rajavtihi neuronal adult stem cells project | Other: progenitor stem cell culture |
| 11 | Not yet recruiting | Autologous mesenchymal stem cell (MSC) transplantation in MS | Biological: autologous mesenchymal stem cell transplantation |
| 12 | Completed | Phase I study of high‐dose cyclophosphamide and total body irradiation with T lymphocyte‐depleted autologous peripheral blood stem cell or bone marrow rescue in patients with multiple sclerosis | Drug: cyclophosphamide; Drug: filgrastim; Drug: methylprednisolone; Procedure: autologous stem cell transplantation |
| 13 | Completed | Phase I pilot study of total‐body irradiation, anti‐thymocyte globulin and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell transplantation in patients with multiple sclerosis | Drug: anti‐thymocyte globulin; Drug: cyclophosphamide; Drug: filgrastim; Drug: prednisone; Procedure: peripheral blood stem cell transplantation; Procedure: irradiation |
| 14 | Recruiting | Nonmyeloablative allo stem cell transplant for severe autoimmune diseases | Procedure: nonmyeloablative allogeneic stem cell transplant |
| 15 | Recruiting | Oligodendrocyte progenitor cell culture from human brain | Procedure: oligodendrocyte progenitor cell culture/craniotomy |
| 16 | Recruiting | Scleroderma: cyclophosphamide or transplantation (SCOT) | Procedure: autologous stem cell transplantation and high‐dose immunosuppressive therapy (HDIT); Drug: cyclosphosphamide; Drug: equine antithymocyte drug: methylprednisolone; Drug: growth colony stimulating factor (G‐CSF); Radiation: total body irradiation (TBI) |
| 17 | Recruiting | Allogeneic mesenchymal stem cells transplantation for systemic sclerosis (SSc) | Biological: allogeneic mesenchymal stem cells (AlloMSC) |
| 18 | Active, | Development of iPS from donated somatic cells of patients with neurological diseases | |
| not recruiting |